Skip to main content
. 2021 Nov;27(11):2919–2922. doi: 10.3201/eid2711.211886

Figure 2.

Figure 2

Vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 infection in adolescents 12–15 years of age, by time after second dose of BNT162b2 vaccine (Pfizer-BioNTech, https://www.pfizer.com), Israel, 2021. Error bars indicate 95% CIs.